P2B-001 Market Size, Forecast, and Emerging Insight - 2032
상품코드:1462267
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
약제 요약
Pharma Two B가 개발중인 P2B-001은 저용량 도파민 작용제인 서방형 프라미펙솔과 저용량 모노아민 산화효소 B(MAO-B) 억제제인 라사길린의 1일 1회 투여하는 새로운 병용요법으로, 파킨슨병 치료제로서 특별히 개발되었습니다.
이 두 약제는 서로 다른 두 가지 메커니즘으로 작용하기 때문에 함께 사용하면 각각의 약제보다 더 나은 효과를 얻을 수 있다고 생각되는 이유가 있습니다. 치료 효과를 잃지 않고 더 낮은 용량으로 사용할 수 있습니다. 따라서 P2B001의 개발은 이 두 약물의 저용량 조합을 개선된 제형으로 제공하는 것을 목표로 하고 있으며, 각각의 약물을 단독으로 복용하거나 현재 시판되고 있는 약물을 병용하는 것보다 파킨슨병 증상을 더 잘 억제하고 부작용이 적을 것으로 예상됩니다. 기대되고 있습니다.
Pharma Two B는 P2B001의 초기 파킨슨병에 대한 1일 1회 무투약 치료제로서의 유효성과 안전성을 조사하는 임상 IIb상 및 임상 III상 시험을 완료했으며, FDA에 NDA를 신청하기 위해 준비 중에 있습니다. 이미 완료된 임상시험에서 P2B001을 투여한 환자들은 위약을 투여한 환자들에 비해 파킨슨병 증상이 유의미하게 개선된 것으로 나타났습니다.
주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 파킨슨병용 P2B-001에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.
목차
제1장 리포트의 서론
제2장 파킨슨병에서의 P2B-001 개요
제품의 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
기타 개발 활동
제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 신치료법)
제5장 P2B-001 시장 평가
파킨슨병에서 P2B-001의 시장 전망
주요 7 시장 분석
주요 7 시장 파킨슨병용 P2B-001의 시장 규모
시장 분석 : 국가별
미국의 파킨슨병용 P2B-001의 시장 규모
독일의 파킨슨병용 P2B-001의 시장 규모
영국의 파킨슨병용 P2B-001의 시장 규모
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 리포트 구입 옵션
KSA
영문 목차
영문목차
"P2B-001 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about P2B-001 for Parkinson's disease in the seven major markets. A detailed picture of the P2B-001 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the P2B-001 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the P2B-001 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
Drug Summary:
P2B-001 being developed by Pharma Two B, is a novel, once-daily combination of extended-release pramipexole, a low-dose dopamine agonist, and rasagiline, a low-dose Monoamine Oxidase-B (MAO-B) inhibitor, developed specifically for the treatment of Parkinson's disease.
The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each drug. Lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs in an improved formulation that is hoped to be more effective in controlling Parkinson's disease symptoms and with fewer side effects than each of the drugs taken alone or the currently available commercial drugs taken together.
Pharma Two B has completed Phase IIb and Phase III studies investigating P2B001's efficacy and safety as a once-daily, no-titration treatment for early-stage Parkinson's disease. An NDA submission to the FDA is being prepared. In a previously completed clinical trial, a significant improvement in Parkinson's disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with a placebo.
Scope of the Report:
The report provides insights into:
A comprehensive product overview including the P2B-001 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
Elaborated details on P2B-001 regulatory milestones and other development activities have been provided in this report.
The report also highlights the P2B-001 research and development activities in Parkinson's disease across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around P2B-001.
The report contains forecasted sales of P2B-001 for Parkinson's disease till 2032.
Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
The report also features the SWOT analysis with analyst views for P2B-001 in Parkinson's disease.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
P2B-001 Analytical Perspective by DelveInsight
In-depth P2B-001 Market Assessment
This report provides a detailed market assessment of P2B-001 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
P2B-001 Clinical Assessment
The report provides the clinical trials information of P2B-001 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence P2B-001 dominance.
Other emerging products for Parkinson's disease are expected to give tough market competition to P2B-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of P2B-001 in Parkinson's disease.
Our in-depth analysis of the forecasted sales data of P2B-001 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the P2B-001 in Parkinson's disease.
Key Questions:
What is the product type, route of administration and mechanism of action of P2B-001?
What is the clinical trial status of the study related to P2B-001 in Parkinson's disease and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the P2B-001 development?
What are the key designations that have been granted to P2B-001 for Parkinson's disease?
What is the forecasted market scenario of P2B-001 for Parkinson's disease?
What are the forecasted sales of P2B-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to P2B-001 for Parkinson's disease?
Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?
